| Betterchem |
|
|
| FDA approval activities
for this prescription drug:
Gleevec (imatinib mesylate) capsules, 100 mg, Novartis NDA 21-335/S-004 12/20/02 1/29/03 12/23/02 7/8/03 Gleevec (imatinib mesylate) capsules, 50 mg and 100 mg, Novartis NDA 21-335/S-003 5/20/03 7/24/03 Gleevec (imatinib mesylate) capsules, 50 mg and 100 mg, Novartis NDA 21-335/S-001 2/1/02 2/1/02 2/1/02 7/8/03 Gleevec Indication: This supplement added an indication for Gastrointestinal Stromal Tumors (GIST) Gleevec (imatinib mesylate) capsules, 50 mg and 100 mg, Novartis NDA 21-335 5/10/01 5/11/01 5/11/01 10/17/01 Gleevec Indication: for the treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. Gleevec (imatinib mesylate) Tablets, 100 and 400 mg, Novartis NDA 21-588 |
© 2007 Betterchem Corp.
|